RARE fundamentals
An in-depth look to Ultragenyx Pharmaceutical Inc. operating, investing, and financing activities
RARE free cash flow for Q3 24 is -68.61 M USD. For 2023, RARE free cash flow was -519.07 M USD and operating cash flow was -474.81 M USD.
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM